Eli Lilly's Weight Loss Drug Zepbound Reduces Heart Failure Risks

Trial results reveal Eli Lilly's weight loss drug, Zepbound, reduces hospitalization, death risks, and other outcomes for obese adults with a common type of heart failure. The medication, also known as tirzepatide, showed a 38% reduction in these risks compared to a placebo.

Trial results have shown that Eli Lilly's weight loss medication, Zepbound, can significantly reduce the risk of hospitalization, death, and other outcomes for obese adults suffering from a common type of heart failure, the company announced on Thursday. This development strengthens the case for the drug's broader health benefits.

Known as tirzepatide in medical terms, Zepbound reduced the risk of a composite of heart failure urgent visits or hospitalization, oral diuretic intensification, or cardiovascular death by 38% compared to a placebo. The randomized trial involved 731 patients across 10 countries, all dealing with heart failure with preserved ejection fraction and obesity.

The condition impacts nearly half of all heart failure cases in the U.S., with almost 60% of those affected also living with obesity, according to Jeff Emmick, Lilly's senior vice president of product development. The trial results indicated that the drug also significantly improved heart failure symptoms and physical limitations.